nx_supply_risk.nx

nx_supply_risk.nx -- GTM SUITE / MANUFACTURING SOURCING + APPROVAL RISK rung. Where to make the material, what importing your own rigor actually costs, and what any of it does to the odds of approval. THE CENTRAL QUESTION THIS ANSWERS: can you buy a cheap manufacturing base and supply the discipline yourself? Largely YES -- GMP is INSPECTION-based, not nationality-based. A facility in Hyderabad holding an EU-GMP certificate and a clean FDA inspection record is legally equivalent to one in Basel, and roughly half of US generic supply already comes from India. Quality Agreements, vendor qualification, person-in-plant and independent lot release are precisely the mechanism for importing rigor, and large sponsors do it every day. BUT THE RIGOR IS NOT FREE, AND THAT IS THE WHOLE FINDING. Model the true cost -- sticker + audit burden + the expected cost of an inspection-driven delay -- and the cheap options CONVERGE. On a $10M API spend the effective costs of India, Poland and China land within a few percent of one another, because the sticker advantage of the cheapest is eaten by its risk premium. Once that is visible, the right basis for choosing is quality of access and regulatory adjacency, NOT the quoted price. Choosing on sticker alone is choosing the risk without pricing it. AN IRONY WORTH NAMING. The dominant failure mode at low-cost sites is DATA INTEGRITY -- falsified or selectively reported records, the Ranbaxy 2013 felony plea being the canonical case. That is the SAME failure mode as the opioid scandal, in a different jurisdiction and a different direction. Fleeing one does not escape the class; only auditing does. ON APPROVAL RISK. FDA does not reject drugs for being foreign -- most new approvals involve foreign data and foreign manufacture. What it does reject is (a) a dataset drawn from a single non-representative population, and (b) a facility that fails inspection. Both are manageable and both are under sponsor control, which is why they are modelled here as inputs rather than as fate. Costs in THOUSANDS of USD; probabilities in per-mil. Grounding (cited; researcher-groundable): fda_foreign_facility_inspection_and_oai_classification ich_q7_gmp_active_pharmaceutical_ingredients